Namodenoson clinical trials
Also written CF102 and Cl-IB-MECA.
How each study uses namodenoson is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the namodenoson studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses namodenoson is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisRecruitingPhase 3Can-Fite BioPharmaNCT05201404Written as Namodenoson
- Namodenoson Treatment of Advanced Pancreatic CancerRecruitingPhase 2Can-Fite BioPharmaNCT06387342Written as Namodenoson 25mg
- Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)RecruitingPhase 2Can-Fite BioPharmaNCT04697810Written as Namodenoson
- Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)CompletedPhase 2Can-Fite BioPharmaNCT02128958Written as CF102
- A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 1/2Can-Fite BioPharmaNCT00790218Written as CF102
- A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver DiseaseCompletedPhase 2Can-Fite BioPharmaNCT02927314Written as CF102
- A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1CompletedPhase 1/2Can-Fite BioPharmaNCT00790673Written as CF 102
Codes
What other systems call namodenoson · ClinicalTrials.gg INT003807
- MeSH (NLM) C0900342-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamideConfirmed NLM, Wikidata
- UNII (FDA) Z07JR07J6CNAMODENOSONConfirmed FDA, NLM, Wikidata
- Wikidata Q27076097namodenosonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79826NamodenosonOne source FDA
- DrugBank DB12885One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C090034 | 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide | Confirmed NLM, Wikidata |
| UNII (FDA) | Z07JR07J6C | NAMODENOSON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27076097 | namodenoson | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79826 | Namodenoson | One source FDA |
| DrugBank | DB12885 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.